Dual-Metal Regulation of Cardiac Remodeling: Targeting the LOXL2-Ferroptosis Axis in Metal-Induced Cardiac Dysfunction
Cardiovascular Toxicology · 2026-08 · 26 (8)
DOI: 10.1007/s12012-026-10167-y ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cardiovascular Toxicology, online erschienen am 31.07.2026. Verfasst von Saif Siddiqui und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, SVKM's Dr. Bhanuben Nanavati College of Pharmacy, Vile Parle (W), Mumbai, India. Hauptthemen laut MEDLINE: Ventricular Remodeling, Myocytes, Cardiac, Amino Acid Oxidoreductases, Ferroptosis. Die Arbeit nennt 115 Literaturangaben.
Abstract (Originalsprache)
Cardiac remodeling is driven by progressive extracellular matrix stiffening and cardiomyocyte loss. Cardiomyocyte death arising from the progression of fibrosis and ferroptosis, which are regulated by interconnected pathogenic pathways such as lysyl oxidase-like (LOXL), Yes-associated protein (YAP) transcriptional coactivator with PDZ-binding motif (TAZ), and transforming growth factor-beta, leads to cardiac remodeling. However, existing treatments are insufficient to restore heart health. There is mounting evidence that maintaining a healthy balance of metals, particularly copper and iron, can protect the heart from metal-induced cell death, cardiac structural remodeling, and extracellular matrix stiffening. This review examines a therapeutic targeting strategy that emphasises the significance of the Cu-LOXL2-Fe-ferroptosis circuit, a mechanometabolic loop that reinforces the extracellular matrix and oxidative cell death. In this dual-chelation approach, copper modulation inhibits LOXL2-driven extracellular matrix stiffening and profibrotic signaling, while iron chelation suppresses iron-dependent lipid peroxidation and ferroptotic cardiomyocyte death. This combined approach provides a more effective treatment window, interrupting the vicious cycle of tissue damage and cardiomyocyte death. There is preliminary evidence that metal chelators may be able to mitigate ferroptosis and fibrosis, which could lead to possible outcomes. Graphical Abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, SVKM's Dr. Bhanuben Nanavati College of Pharmacy, Vile Parle (W), Mumbai, India.
- Department of Pharmacology, SVKM's Dr. Bhanuben Nanavati College of Pharmacy, Vile Parle (W), Mumbai, India. lokesh.bhatt@bncp.ac.in.
Zitieren
APA
Siddiqui, S., Parab, S. B., & Bhatt, L. K. (2026). Dual-Metal Regulation of Cardiac Remodeling: Targeting the LOXL2-Ferroptosis Axis in Metal-Induced Cardiac Dysfunction. Cardiovascular Toxicology, 26(8). https://doi.org/10.1007/s12012-026-10167-y
Vancouver
Siddiqui S, Parab SB, Bhatt LK. Dual-Metal Regulation of Cardiac Remodeling: Targeting the LOXL2-Ferroptosis Axis in Metal-Induced Cardiac Dysfunction. Cardiovascular Toxicology. 2026;26(8). doi:10.1007/s12012-026-10167-y
BibTeX
@article{Siddiqui2026,
author = {Siddiqui, Saif and Parab, Siddhi Bagwe and Bhatt, Lokesh Kumar},
title = {Dual-Metal Regulation of Cardiac Remodeling: Targeting the LOXL2-Ferroptosis Axis in Metal-Induced Cardiac Dysfunction},
journal = {Cardiovascular Toxicology},
year = {2026},
volume = {26},
number = {8},
doi = {10.1007/s12012-026-10167-y}
}
EUVIMED